Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Sales and Divestitures (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 63.05% to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 63.05% increase, with the full-year FY2025 number at $5.1 million, up 63.05% from a year prior.
  • Gains from Sales and Divestitures was $5.1 million for Q4 2025 at Iovance Biotherapeutics, up from $4.7 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $5.1 million in Q4 2025 to a low of $770257.0 in Q1 2023.
  • A 3-year average of $2.5 million and a median of $2.1 million in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: increased 14.28% in 2024, then skyrocketed 304.28% in 2025.
  • Iovance Biotherapeutics' Gains from Sales and Divestitures stood at $1.3 million in 2023, then skyrocketed by 151.32% to $3.2 million in 2024, then skyrocketed by 63.05% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Gains from Sales and Divestitures are $5.1 million (Q4 2025), $4.7 million (Q3 2025), and $4.1 million (Q2 2025).